CNTB Key Statistics, Chart & Performance
The current stock price of CNTB is 2.43 USD. In the past month the price increased by 50.93%. In the past year, price increased by 117.28%.
CNTB Latest News, Press Relases and Analysis
CNTB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.66 | 395.11B | ||
| AMGN | AMGEN INC | 14.52 | 170.94B | ||
| GILD | GILEAD SCIENCES INC | 15.05 | 152.88B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.06 | 114.79B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.44 | 77.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 762.98 | 51.41B | ||
| INSM | INSMED INC | N/A | 41.00B | ||
| NTRA | NATERA INC | N/A | 31.36B | ||
| BIIB | BIOGEN INC | 10.39 | 25.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.66 | 21.20B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.6 | 18.41B |
Related stock screener links
About CNTB
Company Profile
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Company Info
CONNECT BIOPHARMA HOLDINGS L
3580 Carmel Mountain Road, Suite 200
San Diego CALIFORNIA 215400 US
CEO: William Pan
Employees: 62
Phone: 18587271040
CONNECT BIOPHARMA HOLDINGS L / CNTB FAQ
Can you describe the business of CONNECT BIOPHARMA HOLDINGS L?
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
What is the stock price of CONNECT BIOPHARMA HOLDINGS L today?
The current stock price of CNTB is 2.43 USD.
Does CNTB stock pay dividends?
CNTB does not pay a dividend.
What is the ChartMill rating of CONNECT BIOPHARMA HOLDINGS L stock?
CNTB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CNTB stock?
CNTB stock is listed on the Nasdaq exchange.
Can you provide the market cap for CONNECT BIOPHARMA HOLDINGS L?
CONNECT BIOPHARMA HOLDINGS L (CNTB) has a market capitalization of 135.40M USD. This makes CNTB a Micro Cap stock.
Can you provide the ownership details for CNTB stock?
You can find the ownership structure of CONNECT BIOPHARMA HOLDINGS L (CNTB) on the Ownership tab.
CNTB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CNTB. When comparing the yearly performance of all stocks, CNTB is one of the better performing stocks in the market, outperforming 96.1% of all stocks.
CNTB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTB. CNTB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CNTB Financial Highlights
Over the last trailing twelve months CNTB reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 74.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.2% | ||
| ROE | -28.22% | ||
| Debt/Equity | 0 |
CNTB Forecast & Estimates
10 analysts have analysed CNTB and the average price target is 8.06 USD. This implies a price increase of 231.6% is expected in the next year compared to the current price of 2.43.
For the next year, analysts expect an EPS growth of -170.42% and a revenue growth -99.89% for CNTB